1056 related articles for article (PubMed ID: 15833897)
21. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
22. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.
Witkin JM; Levant B; Zapata A; Kaminski R; Gasior M
J Pharmacol Exp Ther; 2008 Sep; 326(3):930-8. PubMed ID: 18566292
[TBL] [Abstract][Full Text] [Related]
23. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
24. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
Millan MJ; Bervoets K; Colpaert FC
J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
[TBL] [Abstract][Full Text] [Related]
25. Dopamine D3 agonists disrupt social behavior in rats.
Kagaya T; Yonaga M; Furuya Y; Hashimoto T; Kuroki J; Nishizawa Y
Brain Res; 1996 May; 721(1-2):229-32. PubMed ID: 8793104
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
[TBL] [Abstract][Full Text] [Related]
27. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
28. Effects of Acute and Chronic Treatments with Dopamine D
Thomsen M; Barrett AC; Butler P; Negus SS; Caine SB
J Pharmacol Exp Ther; 2017 Jul; 362(1):161-176. PubMed ID: 28473458
[TBL] [Abstract][Full Text] [Related]
29. Trace amine-associated receptor 1 agonists RO5263397 and RO5166017 attenuate quinpirole-induced yawning but not hypothermia in rats.
Siemian JN; Zhang Y; Li JX
Behav Pharmacol; 2017 Oct; 28(7):590-593. PubMed ID: 28704278
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic modulation of rat pup ultrasonic vocalizations.
Dastur FN; McGregor IS; Brown RE
Eur J Pharmacol; 1999 Oct; 382(2):53-67. PubMed ID: 10528139
[TBL] [Abstract][Full Text] [Related]
31. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.
Gleason SD; Witkin JM
Behav Pharmacol; 2004 Feb; 15(1):85-9. PubMed ID: 15075630
[TBL] [Abstract][Full Text] [Related]
32. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
33. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
34. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
Gogos A; Kwek P; Chavez C; van den Buuse M
J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
[TBL] [Abstract][Full Text] [Related]
35. Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys.
Gasior M; Paronis CA; Bergman J
J Pharmacol Exp Ther; 2004 Jan; 308(1):249-59. PubMed ID: 14563783
[TBL] [Abstract][Full Text] [Related]
36. Dopamine D2-like receptor agonists induce penile erection in male rats: differential role of D2, D3 and D4 receptors in the paraventricular nucleus of the hypothalamus.
Sanna F; Succu S; Hübner H; Gmeiner P; Argiolas A; Melis MR
Behav Brain Res; 2011 Nov; 225(1):169-76. PubMed ID: 21784104
[TBL] [Abstract][Full Text] [Related]
37. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D2 receptors play a role in the (-)-apomorphine-like discriminative stimulus effects of (+)-PD 128907.
Kleven MS; Koek W
Eur J Pharmacol; 1997 Feb; 321(1):1-4. PubMed ID: 9083778
[TBL] [Abstract][Full Text] [Related]
39. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors.
Dall'Olio R; Gaggi R; Voltattorni M; Tanda O; Gandolfi O
Behav Pharmacol; 2002 Dec; 13(8):633-8. PubMed ID: 12478213
[TBL] [Abstract][Full Text] [Related]
40. Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats.
Li SM; Collins GT; Paul NM; Grundt P; Newman AH; Xu M; Grandy DK; Woods JH; Katz JL
Behav Pharmacol; 2010 May; 21(3):171-81. PubMed ID: 20463460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
